Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)

Phase 3

Completed

• Conditions: Astrocytoma; Glioblastoma
• Interventions: Drug: Temozolomide; Drug: Semustine

• Registration Number: NCT00335075
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03-02
• Primary Completion: 2006-02-23
• Study Completion: 2006-02-23
• Study First Submitted: 2006-06-06
• Study First Submitted QC: 2006-06-06
• Study First Posted: 2006-06-08
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-12
• Last Update Posted: 2017-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 151

Inclusion Criteria

• Prior histologic confirmation of glioblastoma, anaplastic astrocytoma.
• Evidence of tumor progression or recurrence.
• Age >=18 years.
• Karnofsky performance status >=60%.
• Absolute neutrophil count >=1,500/mm^3, platelet count >=100,000/mm^3, hemoglobin >=8g/dL.
• Serum BUN and creatinine <1.5 times upper normal limit of testing laboratory (ULN).
• Total bilirubin and direct bilirubin <1.5 times ULN.
• SGOT, SGPT <3 times ULN; alkaline phosphatase <2 times ULN.
• Life expectancy greater than 3 months.
• Informed consent obtained.
• If palliative radiation is needed, agree to give it prior to initiating chemotherapy with study drug. If palliative radiation is required during treatment with study drug, the patient should be permanently discontinued from further treatment with study drug.
• Women of childbearing potential must use a medically accepted, effective method of contraception.
• Women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug.

Exclusion Criteria

• Chemotherapy (excluding nitrosourea, mitomycin C or vincristine), biologic therapy or immunotherapy within 4 weeks, inclusive, prior to study drug administration.
• Nitrosourea or mitomycin C administration within 6 weeks, inclusive, prior to study drug administration.
• Vincristine within 2 weeks prior to study drug administration.
• Completion of radiation therapy, interstitial brachytherapy or radiosurgery within 4 weeks prior to study drug administration.
• Surgery within 3 weeks, inclusive, prior to study drug administration.
• Acute infection requiring intravenous antibiotics.
• Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction).
• Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
• Known HIV positive or AIDS-related illness.
• Pregnant or nursing women.
• Men who are not advised to use an effective method of contraception.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Temodal group	Temozolomide	Subjects treated with temozolomide.
Semustine group	Semustine	Subjects treated with semustine.

Primary Outcome Measures

Name	Time	Method
Progression-free survival	2 months, 3 months, and 6 months

Secondary Outcome Measures

Name	Time	Method
Overall survival	6 months
Objective response	6 months
Scoring of health-related quality of life	6 months